Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States

Hiral Anil Shah (), Ginita Jutlla, Oscar Herrera-Restrepo, Jonathan Graham, Katherine A. Hicks, Justin Carrico, Mei Grace, Diana E. Clements, Cindy Burman, Woo-Yun Sohn, Elise Kuylen, Shahina Begum and Zeki Kocaata
Additional contact information
Hiral Anil Shah: GSK
Ginita Jutlla: GSK
Oscar Herrera-Restrepo: GSK
Jonathan Graham: RTI Health Solutions
Katherine A. Hicks: RTI Health Solutions
Justin Carrico: GSK
Mei Grace: RTI Health Solutions
Diana E. Clements: GSK
Cindy Burman: GSK
Woo-Yun Sohn: GSK
Elise Kuylen: GSK
Shahina Begum: GSK
Zeki Kocaata: GSK

PharmacoEconomics, 2025, vol. 43, issue 3, No 6, 329 pages

Abstract: Abstract Background Invasive meningococcal disease (IMD) is primarily associated with five Neisseria meningitidis serogroups: A, B, C, W, or Y. In the United States (US), available vaccines protect against serogroups B (MenB), A, C, W, and Y (MenACWY), and A, B, C, W, and Y (MenABCWY). The Advisory Committee on Immunization Practices is re-evaluating the adolescent meningococcal vaccination schedule with varying recommendation formats. This analysis aimed to predict which schedule could avert the most IMD cases and have the most positive public health impact (PHI). Methods An epidemiological model compared the 15-year PHI of vaccination schedules using MenB, MenACWY, and/or MenABCWY vaccines versus current US standard of care (SoC). Varying coverage rates reflected routine, shared clinical decision making, and risk-based recommendations. Sensitivity analyses assessed robustness of the results to different inputs/assumptions. Results The most positive PHI compared with SoC was observed with one dose of MenACWY at 11 years of age and two doses of MenABCWY (6 months apart) at 16 years of age, assuming routine recommendation and coverage reflecting real-world uptake of MenACWY. This strategy resulted in 123 IMD cases averted (MenB: 59, MenACWY: 64), 17 deaths prevented, 574 life-years saved, and 757 quality-adjusted life-years gained versus SoC. Eliminating MenACWY vaccination at 11 years was found to result in an additional IMD burden. Conclusion A routinely recommended two-dose pentavalent vaccine, with doses administered 6 months apart at 16 years of age, alongside the routinely recommended MenACWY vaccine at 11 years of age, would improve the PHI and benefits of IMD vaccination to society. Graphical Abstract

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-024-01439-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:43:y:2025:i:3:d:10.1007_s40273-024-01439-y

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-024-01439-y

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().